{"data":{"type":"company_profile","id":165240,"entity_id":"wefunder:company:165240","attributes":{"canonical_url":"https://wefunder.com/eliaz.therapeutics","generated_at":"2026-06-15T10:28:12Z","updated_at":"2026-06-15T05:01:22Z","entity_ids":{"company":"wefunder:company:165240","slug":"wefunder:company_slug:eliaz.therapeutics"},"profile_visibility":{"owner_published":true,"public_search_results":true,"site_search_listed":true,"privacy_mode":"promote","invite_only":false},"provenance":{"source":"wefunder_public_company_profile","as_of":"2026-06-15T10:28:12Z","claims":{"total_amount_raised":{"source":"FrontCompanySummary#amount_raised","last_verified_at":"2026-06-15T05:01:22Z","as_of":"2026-06-15T10:28:12Z","confidence":"high"},"total_investors":{"source":"FrontCompanySummary#number_of_investors","last_verified_at":"2026-06-15T05:01:22Z","as_of":"2026-06-15T10:28:12Z","confidence":"high"},"active_raise_states":{"source":"Fundraise.visible(nil, nil)","last_verified_at":"2025-06-05T18:35:42Z","as_of":"2026-06-15T10:28:12Z","confidence":"high"},"latest_fundraise_state":{"source":"Fundraise.visible(nil, nil).order(funding_started_at)","last_verified_at":"2025-06-05T18:35:42Z","as_of":"2026-06-15T10:28:12Z","confidence":"medium"}}},"company":{"id":165240,"entity_id":"wefunder:company:165240","slug":"eliaz.therapeutics","name":"Eliaz Therapeutics","tagline":"Join The Fight Against Sepsis With Our Life-Saving Medical Device: XGal-3®","story":"Click here to view our pitch deck.Why Eliaz Therapeutics?We’re honored to announce that the FDA has awarded XGal-3® its Breakthrough Device Designation!In the medical world, this designation is highly coveted for many reasons.It validates technologies that address urgent, unmet medical needs. It gives patients timely access to innovative treatments that are highly vetted for safety and effectiveness. And often, it offers hope where there is none.At Eliaz Therapeutics, achieving this milestone represents decades of intensive research coming to fruition. But for our supporters and investors, it represents a tremendous opportunity to help address one of medicine’s most urgent challenges.For over three decades, I've dedicated my life to innovating healthcare solutions that alleviate human suffering. This journey led me to develop Pectosol, a natural Galectin-3 blocker backed by nearly 100 research papers, and build a community of over 300,000 health enthusiasts through my integrative medicine work.The tragic loss of my father to immune dysregulation underlying sepsis ignited a personal mission to combat inflammatory conditions. This led to the creation of XGal-3®, a groundbreaking device designed to halt sepsis progression by targeting Galectin-3, a protein driving the deadly inflammatory process.Our patented technology, supported by 2 prestigious NIH grants and protected by over 60 patents across 34 countries, has the potential to stop sepsis within hours. With our world-class team, we've developed a working prototype and are rapidly advancing towards clinical trials.Back in 2023, ecoNugenics, my previous venture, was successfully acquired by a prestigious private equity company, demonstrating our team's ability to create and realize the value in the healthcare sector.Now, as an investor in Eliaz Therapeutics, you have the opportunity to support a movement—one with the potential to save millions of lives across the world.I sincerely hope you join us in the fight against sepsis.Invest in Eliaz Therapeutics today!Sepsis is a Silent Killer That Claims 11 Million Lives AnnuallySepsis strikes without warning, claiming a life every 2.8 seconds. Despite its devastating impact, it remains largely overlooked in public health discussions. This silent killer turns routine infections into catastrophic bodily responses, leading to rapid organ failure and death.Throughout my career, I've witnessed sepsis devastate countless patients and families. This deadly condition imposes a staggering $62 billion annual burden on the U.S. healthcare system. Current treatments only manage symptoms, neglecting the root cause of sepsis. There is no effective therapy targeting the underlying inflammatory process. Our groundbreaking research at Eliaz Therapeutics aims to change this paradigm, offering hope where none existed before.WHEN GOOD PROTEINS GO ROGUEGalectin-3 is a key driver of sepsis when released into the bloodstream. During sepsis and acute kidney injury (AKI), it triggers a cascade of harmful effects.EFFECTS OF GALECTIN-3 IN SEPSIS AND AKIInflammationDisease progressionOrgan fibrosisIncreased morbidity and mortalityDISEASES ASSOCIATED WITH GALECTIN-3:SepsisKidney diseases (AKI, CKD)Heart diseaseLiver cirrhosisCancer\u0026nbsp;\u0026nbsp;Pulmonary hypertensionStrokeDiabetesAutoimmune diseasesNeuroinflammatory diseasesIntroducing XGal-3®: A New Hope for Sepsis PatientsXGal-3® is a medical device that works like dialysis but with a crucial difference. Using proprietary anti-Galectin-3 antibody traps, it targets and removes Galectin-3 from the bloodstream, potentially halting sepsis progression. By disrupting the pathological cascade, XGal-3® aims to prevent the devastating inflammatory cascade and organ damage, and save lives. This targeted approach tackles the root cause of sepsis, offering new hope for millions.\u0026nbsp;HOW IT WORKS:We connect the patient to XGal-3® using standard IV linesBlood flows through our device and is separated into plasma and cellular componentsXGal-3® removes the harmful Galectin-3 protein from the plasmaThe cleansed blood returns to the patientThe whole process takes just hours, potentially saving the patient's lifeFrom Concept to BreakthroughCreated XGal-3® prototype: A first-of-its-kind sepsis treatmentProtected innovation: 60+ patents in 34 countriesValidated by NIH: Secured 2 research grantsPartnered with Terumo: Global leader in medical apheresis technologyExpanded collaborations: Teamed with a multi-billion dollar diagnostics leaderA $1.97 Trillion Global Market Desperate for InnovationXGal-3® targets a massive $1.97 trillion global market. Our vision is to:Transform the treatment for inflammatory and fibrotic diseasesSave \u0026amp; improve millions of lives worldwideStart with sepsis, then expand to broader applicationsOUR STRATEGY:Target Septic Shock First: Address the urgent unmet need in ICUs, where mortality rates can reach up to 60%Strategic Relationships: Collaborate with global apheresis leader for rapid hospital adoptionMaximize Distribution: Partner with distributors, Group Purchasing Organizations, and hospital networks for widespread adoptionDiversify Revenue: Combine direct sales with strategic licensing opportunitiesExpand Applications: Explore XGAL-3®'s potential in AKI, chronic kidney disease, cancer, and fibrosisOur Team is Led by World-Class Experts from Stanford, Mayo Clinic, and leading Biotech CompaniesI'm incredibly proud of the team we've assembled at Eliaz Therapeutics. We've come together from diverse backgrounds in medicine, research, and business, but we're united by a deep commitment to making a difference in the lives of millions.\u0026nbsp;The Perfect StormWe’re at a critical juncture:\u0026nbsp;COVID-19 highlighted the urgent need for effective sepsis treatmentsMedical community more open to innovative approachesOur working prototype is ready for clinical trialsThe global sepsis treatment market is projected to grow due to aging populations and increasing chronic disease prevalenceTogether, We Can Bring X-Gal-3® to Market and Save Millions of LivesBy investing in Eliaz Therapeutics, you're helping us turn \"goodbye\" into \"welcome home\" for families around the world. Let’s defeat sepsis by making XGal-3®\u0026nbsp;standard equipment in every ICU, saving lives daily.\u0026nbsp;Your investment directly supports:Completing crucial safety and efficacy trials with the FDA to bring XGal-3® to market.Bringing hope to millions facing sepsis and other life-threatening conditionsRevolutionizing the way sepsis and other conditions are treated in hospitals around the world.","location":"Santa Rosa, CA","website":"https://www.eliaztherapeutics.com/","total_amount_raised":2509175,"total_investors":1242,"is_funded":true,"is_active":true,"quality_score":5,"related_urls":["https://wefunder.com/eliaz.therapeutics","https://www.eliaztherapeutics.com/"]},"media":{"share_image_url":"https://uploads.wefunder.com/uploads/company/header_media_photo/165240/xxl_blob.jpg","logo_url":"https://uploads.wefunder.com/uploads/company/logo/165240/large_blob","header_media_url":"https://uploads.wefunder.com/uploads/company/header_media_photo/165240/standard_blob.jpg","cover_photo_url":"https://uploads.wefunder.com/uploads/company/header_media_photo/165240/standard_blob.jpg"},"links":{"company_url":"https://www.eliaztherapeutics.com/","linkedin_url":"https://linkedin.com/company/eliaztherapeuticsinc/","youtube_url":"https://youtube.com/watch?v=cdi3H2m551o"},"highlights":[{"id":62736,"name":"notable_angel","url":"notableangel","presentable_name":"Notable Angel","description":"Raised $25k or more from a notable angel investor","image_url":"https://uploads.wefunder.com/2021/profile-highlights-check.svg"}],"quick_facts":[{"index":1,"claim_id":"claim-fact-1","value":"Awarded FDA Breakthrough Device Designation, validating XGal-3®'s potential to save millions"},{"index":2,"claim_id":"claim-fact-2","value":"Addressing critical unmet need: first significant advancement in sepsis treatment in 25 years"},{"index":3,"claim_id":"claim-fact-3","value":"Targeting a $62B sepsis treatment market in the USA alone, part of a $1.97T global opportunity"},{"index":4,"claim_id":"claim-fact-4","value":"Our technology shuts down the sepsis process within hours in large animal studies"},{"index":5,"claim_id":"claim-fact-5","value":"Platform technology with potential applications beyond sepsis, including cancer \u0026amp; fibrotic diseases"},{"index":6,"claim_id":"claim-fact-6","value":"Over 60 patents across 34 countries securing our innovative technology"},{"index":7,"claim_id":"claim-fact-7","value":"Secured 2 prestigious NIH grants, demonstrating scientific merit and potential for commercialization"},{"index":8,"claim_id":"claim-fact-8","value":"Strategic partnership with Terumo BCT for development and commercialization of XGal-3® treatment"}],"team":[{"id":5219438,"entity_id":"wefunder:company_role:5219438","user_entity_id":"wefunder:user:4534864","role":"founder","name":"Dr. Isaac Eliaz (MD)","title":"CEO","bio":"Physician and innovator in conventional and integrative medicine with 30+ years in Galectin-3 research. Founded a high-impact venture acquired by a private equity firm (AUM $22B+), holds 60+ patents, and is driven to create transformative global impact.","avatar_url":"https://uploads.wefunder.com/uploads/company_role/custom_photo/5219438/square_blob.jpg?1754671147","profile_url":"https://wefunder.com/isaac.eliaz","personal_url":"https://www.eliaztherapeutics.com","linkedin_url":"https://linkedin.com/in/dr-isaac-eliaz-489b4629/","related_urls":["https://wefunder.com/isaac.eliaz","https://www.eliaztherapeutics.com"]},{"id":5222414,"entity_id":"wefunder:company_role:5222414","user_entity_id":"wefunder:user:4472081","role":"employee","name":"Anat Stern","title":"COO \u0026 Biz Dev ","bio":"Over 18 years in healthcare and biotech. Led ecoNugenics for 7 yrs to a successful acquisition. Holds an MBA, BSc, and MSc in Biochemistry, combining scientific expertise and business acumen to drive innovation, growth, and success in complex environment.","avatar_url":"https://uploads.wefunder.com/uploads/company_role/custom_photo/5222414/square_blob.jpg?1729935959","profile_url":"https://wefunder.com/anat.stern","linkedin_url":"https://linkedin.com/in/anat-stern-1a6b1120/","related_urls":["https://wefunder.com/anat.stern"]},{"id":5222415,"entity_id":"wefunder:company_role:5222415","role":"employee","name":"Milton Goss","title":"CFO","bio":"An accomplished finance executive with more than 20 years of experience in the medical device, life science, and semiconductor industries. Milton has had a particular emphasis on strategy, business modeling, operations, and M\u0026amp;A.","avatar_url":"https://uploads.wefunder.com/uploads/company_role/custom_photo/5222415/square_blob.jpg?1738497925","linkedin_url":"https://linkedin.com/in/miltongoss/","related_urls":[]},{"id":5288435,"entity_id":"wefunder:company_role:5288435","user_entity_id":"wefunder:user:4533147","role":"employee","name":"Bryan Knipe","title":"Investor relations ","bio":"With an MBA and 20+ years of experience in financial management, business development, and M\u0026amp;A, Bryan has scaled ventures across healthcare and medtech. He specializes in securing capital, go-to-market strategies, and fostering relationships for growth.","avatar_url":"https://uploads.wefunder.com/uploads/company_role/custom_photo/5288435/square_blob.jpg?1729936064","profile_url":"https://wefunder.com/bryan.knipe","linkedin_url":"https://linkedin.com/in/bryan-m-knipe-mba-abb9815/","related_urls":["https://wefunder.com/bryan.knipe"]},{"id":5464681,"entity_id":"wefunder:company_role:5464681","role":"employee","name":"Susan Alpert ","title":"Senior Regulatory Strategist","bio":"Dr. Susan Alpert, former FDA Director, oversaw key medical device approvals during her 13-year tenure. As Medtronic’s Senior VP, she led global regulatory efforts, securing approvals and expanding market access for innovative medical devices worldwide.","avatar_url":"https://uploads.wefunder.com/uploads/company_role/custom_photo/5464681/square_blob.jpg?1738498768","related_urls":[]},{"id":5222416,"entity_id":"wefunder:company_role:5222416","role":"employee","name":"Glenn M Chertow MD","title":"Director of Medical Affairs","bio":"Chief of Nephrology division and a Clinical Research Professor at Stanford School of Medicine and is among the world’s foremost experts in AKI \u0026amp; CKD.","avatar_url":"https://uploads.wefunder.com/uploads/company_role/custom_photo/5222416/square_blob.jpg?1738498768","related_urls":[]},{"id":5788669,"entity_id":"wefunder:company_role:5788669","role":"employee","name":"Dale Cumming ","title":"VP of Research \u0026 Development ","bio":"A biotech expert with 25+ years of experience, including senior roles at Genetics Institute and GlycoDesign. He co-founded Translational Medicines and served as CSO of an international glycobiology therapeutics consortium.","avatar_url":"https://uploads.wefunder.com/uploads/company_role/custom_photo/5788669/square_blob.jpg?1754671166","related_urls":[]}],"featured_investors":[{"id":10131,"entity_id":"wefunder:company_investor_profile:10131","investor_profile_id":3961686,"investor_profile_entity_id":"wefunder:investor_profile:3961686","subject_entity_id":"wefunder:user:4470612","name":"Nathan Crane","role_title":"","bio":"Certified professional nutrition coach, bestselling author, award winning natural health researcher, and plant powered athlete.","avatar_url":"https://wefunder.com/rails/active_storage/blobs/redirect/eyJfcmFpbHMiOnsiZGF0YSI6MTkyNjE0LCJwdXIiOiJibG9iX2lkIn19--c020d977b25b239847c190a63a913f7bccd45452/filename","profile_url":"https://wefunder.com/nathan.crane","endorsement_quote":"An investment in ETI is a no-brainer for me. For someone who cares deeply about the health and well-being of humanity, seeing this powerful new technology come to market that could save millions of people's lives by implementing a non-toxic approach in healthcare is exactly what we need at this time. There's no one better to bring it to the world than Dr. Isaac Eliaz. I believe this investment opportunity will change lives and give a powerful financial opportunity for growth, and I'm very happy to be a part of it.","endorsement_name":"","investment_total":107500,"investment_info":"Invested $7,500 this round \u0026 $100,000 previously","is_lead_investor":true,"memo_paid_for_by_company":false,"related_urls":["https://wefunder.com/nathan.crane"]},{"id":10156,"entity_id":"wefunder:company_investor_profile:10156","investor_profile_id":4024515,"investor_profile_entity_id":"wefunder:investor_profile:4024515","subject_entity_id":"wefunder:notable_investor:13780","name":"Russell L. Brand ","role_title":"","bio":"An MIT graduate, entrepreneur, and angel investor, currently serving as Founder and Managing Director of Responsible Solutions Ltd. He focuses on information technology and business consulting","avatar_url":"https://wefunder.com/rails/active_storage/blobs/redirect/eyJfcmFpbHMiOnsiZGF0YSI6MjY1ODQ3LCJwdXIiOiJibG9iX2lkIn19--a2323e6aa6f59d46f9b4acc90497da921f794743/filename","profile_url":"https://wefunder.com/russell.l.brand..1","endorsement_quote":"I have started 3 successful technology companies and invested in many more. The largest investment I have made personally is in Eliaz Therapeutics. Excessive galectin-3 is directly responsible for the majority of in-hospital deaths including those from sepsis, the need for many organ transplants, and massive avoidable suffering. Eliaz Therapeutics is making a blood filter that removes Excessive galectin-3 and can prevent those deaths and much of that suffering. Because it is an external device it can work much more rapidly and safely than a pharmacological intervention and can more quickly receive regulator approval. I see it as one of the most important medical advances of our time.","endorsement_name":"","is_lead_investor":false,"memo_paid_for_by_company":false,"related_urls":["https://wefunder.com/russell.l.brand..1"]},{"id":10267,"entity_id":"wefunder:company_investor_profile:10267","investor_profile_id":4039463,"investor_profile_entity_id":"wefunder:investor_profile:4039463","subject_entity_id":"wefunder:notable_investor:13890","name":"Glenn Chertow","role_title":"","bio":"Physician-investigator (nephrologist), Stanford University, member of the National Academy of Medicine","avatar_url":"https://wefunder.com/rails/active_storage/blobs/redirect/eyJfcmFpbHMiOnsiZGF0YSI6MjQ2NjAyLCJwdXIiOiJibG9iX2lkIn19--add795afcfe0be7bc7ea0002d2b02c6eb76381c1/filename","profile_url":"https://wefunder.com/glenn.chertow","endorsement_quote":"Sepsis-associated acute kidney injury is a devastating condition for which there are no approved treatments. Higher serum galectin-3 concentrations are associated with adverse outcomes and can be sharply reduced with the extracorporeal adsorption column developed by ETI. A safe, effective treatment for acute kidney injury in critically ill patients could save lives and reduce the burden of maintenance dialysis for patients who survive but whose kidneys fail to recover. I have been waiting more than 30 years for something that could offer hope to patients with sepsis-associated acute kidney injury. I feel compelled to support ETI and the development of this product with a combination of a modest financial investment, and a more considerable investment of my time, effort, and expertise.","endorsement_name":"","is_lead_investor":false,"memo_paid_for_by_company":false,"related_urls":["https://wefunder.com/glenn.chertow"]},{"id":10155,"entity_id":"wefunder:company_investor_profile:10155","investor_profile_id":4024511,"investor_profile_entity_id":"wefunder:investor_profile:4024511","subject_entity_id":"wefunder:notable_investor:13778","name":"Cyrus Khambatta","role_title":"","bio":"PhD in Nutritional Biochemistry. New York Times bestselling author of Mastering Diabetes and co-founder of amlagreen.com","avatar_url":"https://wefunder.com/rails/active_storage/blobs/redirect/eyJfcmFpbHMiOnsiZGF0YSI6MjM0NTI3LCJwdXIiOiJibG9iX2lkIn19--1e7bd4358a768a611fcb3051e426284b6dac457c/filename","profile_url":"https://wefunder.com/cyrus.khambatta","endorsement_quote":"I’ve been in the world of chronic disease prevention for 20 years and have come across many companies attempting to reduce the burden of many chronic conditions. When I saw ETI’s data in preventing AKI in pre-clinical sepsis models, I was blown away by the effectiveness of treatment with the X-Gal column. The mortality \u0026amp; healthcare costs associated with treating sepsis and sepsis-related injuries is massive, and I’m honoured to be able to help ETI develop a treatment for use in the ICU that’s quick, effective, and life-saving.","endorsement_name":"","is_lead_investor":false,"memo_paid_for_by_company":false,"related_urls":["https://wefunder.com/cyrus.khambatta"]}],"investor_memos":[],"tab_counts":{"posts":21,"ask_questions":70,"featured_investors":4,"faq_entries":5},"active_fundraises":[{"id":124995,"entity_id":"wefunder:fundraise:124995","state":"successful","offering_type":"4(a)(6)","funding_type":"note","structure":"ttw","security_type":"","currency":"USD","testing_the_waters":true,"min_purchase":250,"max_purchase":9,"funding_target":3000000.0,"minimum_target":"50000.0","maximum_target":"3000000.0"},{"id":124994,"entity_id":"wefunder:fundraise:124994","state":"successful","offering_type":"4(a)(6)","funding_type":"note","structure":"safe","security_type":"equity","currency":"USD","testing_the_waters":false,"min_purchase":250,"max_purchase":9,"funding_target":50000.0,"minimum_target":"50000.0","maximum_target":"3000000.0","funding_started_at":"2024-11-07T18:38:32Z","funding_closed_at":"2025-10-01T03:59:59Z","auto_close_at":"2025-10-01T03:59:59Z"}],"latest_fundraise":{"id":124995,"entity_id":"wefunder:fundraise:124995","state":"successful","offering_type":"4(a)(6)","structure":"ttw","testing_the_waters":true,"can_invest_now":false,"funding_started_at":null,"funding_closed_at":null,"terms":{"eb":null,"nb":"$49.5M","txt":"valuation cap"}},"recent_posts":[{"id":193613,"entity_id":"wefunder:feed_item:193613","type":"FeedItem::Update","visibility":"public","title":"To Our Investors: This Is Just the Beginning","preview":"To our incredible community of investors and supporters,\u0026nbsp;What you've helped us accomplish is nothing short of remarkable! With your trust and commitment, we’ve raised $3.19M to advance a technology with the potential to fundamentally transform how medicine tackles sepsis.This milestone is only the beginning — and it wouldn’t have been possible without you.With deep appreciation,Isaac and the Team","published_at":"2025-10-01T04:52:08Z","author_name":"Dr. Isaac Eliaz (MD)","url":"/feed/193613","canonical_url":"https://wefunder.com/feed/193613"},{"id":193499,"entity_id":"wefunder:feed_item:193499","type":"FeedItem::Update","visibility":"public","title":"My Life’s Work Has Led to This Moment","preview":"With less than 2 days left in our Wefunder campaign, I find myself reflecting on the journey that has brought us here.When I began researching Galectin-3 more than 30 years ago, it was a lonely and uncertain field. The role of this protein in driving inflammation, organ failure, and mortality was largely overlooked. Today, thousands of scientific papers validate what once felt like a solitary pursuit.What began as theory has become a prototype and now, with your support, is on the verge of re...","published_at":"2025-09-28T08:48:56Z","author_name":"Dr. Isaac Eliaz (MD)","url":"/feed/193499","canonical_url":"https://wefunder.com/feed/193499"},{"id":192569,"entity_id":"wefunder:feed_item:192569","type":"FeedItem::Update","visibility":"public","title":"Why This Mission Matters","preview":"Every year, sepsis strikes over 49 million people worldwide, including more than 2 million Americans, and causes 11 million deaths. For me, this mission is deeply personal. I lost my father to immune dysregulation underlying sepsis. That experience set me on a path to dedicate my life to understanding Galectin-3 and building therapies aimed at saving lives.With the support of over 1,000 investors, we’re closer than ever to making a difference. Together, we can help bring a new option to patie...","published_at":"2025-09-21T07:33:27Z","author_name":"Dr. Isaac Eliaz (MD)","url":"/feed/192569","canonical_url":"https://wefunder.com/feed/192569"},{"id":184834,"entity_id":"wefunder:feed_item:184834","type":"FeedItem::Update","visibility":"public","title":"TRACK RECORD OF SUCCESS - From ecoNugenics to Eliaz Therapeutics","preview":"To our valued Wefunder community,In 2023, a leading private equity firm acquired my previous venture, ecoNugenics, after I had spent three decades building a company that helped hundreds of thousands of patients worldwide.At ecoNugenics, we achieved something remarkable: growing from a research-driven startup into a global leader in natural medicine, with clinically validated products adopted by top medical institutions.Now, at Eliaz Therapeutics, I’ve reunited with the key team members who d...","published_at":"2025-08-18T10:49:03Z","author_name":"Dr. Isaac Eliaz (MD)","url":"/feed/184834","canonical_url":"https://wefunder.com/feed/184834"},{"id":184278,"entity_id":"wefunder:feed_item:184278","type":"FeedItem::Update","visibility":"public","title":"This Changes Everything for Investors","preview":"To our valued Wefunder community,I’ve had a couple of weeks now to reflect on my trip to the 15th ISFA World Congress in Bangkok, and I’m still feeling the energy from the event. The theme was “Apheresis for Tomorrow,” and being there truly felt like we were stepping directly into that future.Over the course of countless conversations with many of the world’s leading minds in apheresis, I witnessed an undeniable sense of urgency to move beyond older, less selective methods. What became profou...","published_at":"2025-07-31T20:07:07Z","author_name":"Dr. Isaac Eliaz (MD)","url":"/feed/184278","canonical_url":"https://wefunder.com/feed/184278"},{"id":184178,"entity_id":"wefunder:feed_item:184178","type":"FeedItem::Update","visibility":"public","title":"MAJOR MILESTONE - FIRST PATIENT ENROLLED IN DIAGNOSTIC TRIALS","preview":"Dear Eliaz Therapeutics followers \u0026 investor,I am deeply humbled to announce that we’ve officially enrolled the first patient in our diagnostic clinical study at Tel Aviv Sourasky (Ichilov) Medical Center, a hospital ranked among the world's very best.This means that for the first time ever, we will systematically monitor the real-time level of Galectin-3 in critically ill sepsis patients during their ICU stay. By tracking these Galectin-3 dynamics, we aim to uncover the precise patterns that...","published_at":"2025-07-28T21:55:55Z","author_name":"Dr. Isaac Eliaz (MD)","url":"/feed/184178","canonical_url":"https://wefunder.com/feed/184178"},{"id":184095,"entity_id":"wefunder:feed_item:184095","type":"FeedItem::Update","visibility":"public","title":"Washington is Mobilizing Against Sepsis. But is it Enough?","preview":"Dear friends,Last month, the U.S. Senate reintroduced the bipartisan SEPSIS Act1 to funnel national resources toward better care and data collection. This comes at a critical time in our fight against sepsis as new federal data shows a nearly 40% increase2 in sepsis hospitalizations between 2016 and 2021.\u0026nbsp;This national spotlight is a significant step forward. But, as a physician who has watched families and patients fight what is often a lonely battle against an extremely deadly conditio...","published_at":"2025-07-24T20:57:37Z","author_name":"Dr. Isaac Eliaz (MD)","url":"/feed/184095","canonical_url":"https://wefunder.com/feed/184095"},{"id":183843,"entity_id":"wefunder:feed_item:183843","type":"FeedItem::Update","visibility":"public","title":"Your Investment on the Global Stage","preview":"To our valued Wefunder community,\u0026nbsp;Earlier this week, we shared our commitment to addressing the global sepsis crisis where it hits hardest.\u0026nbsp;Today, I am writing to you from the front lines of that mission at the 15th International Society for Apheresis World Congress in Bangkok, the world’s leading forum for apheresis science and clinical application.This event brings together:Top physicians and intensivists treating critically ill patients worldwideRenowned researchers advancing ext...","published_at":"2025-07-17T10:52:07Z","author_name":"Dr. Isaac Eliaz (MD)","url":"/feed/183843","canonical_url":"https://wefunder.com/feed/183843"},{"id":183474,"entity_id":"wefunder:feed_item:183474","type":"FeedItem::Update","visibility":"public","title":"Will you take one more step and help us share this mission?","preview":"Dear friends,Right now, we’re building something that could finally change the outcome of one of the deadliest medical emergencies on the planet: sepsis. Looking ahead, your support brings XGal-3® one step closer to reaching the patients who need it most. \u0026nbsp; ♥️ Click here to share our Wefunder campaign That single action helps us stand against a crisis that claims millions of lives. It empowers our work to bring XGal-3® to market, offering a future where sepsis is no longer a death senten...","published_at":"2025-07-07T12:00:53Z","author_name":"Dr. Isaac Eliaz (MD)","url":"/feed/183474","canonical_url":"https://wefunder.com/feed/183474"},{"id":183434,"entity_id":"wefunder:feed_item:183434","type":"FeedItem::Update","visibility":"public","title":"Why are Top Scientists Suddenly Adopting Our 30-Year-Old Strategy?","preview":"Dear friends,For decades, a truly effective treatment for sepsis was out of reach.\u0026nbsp;As a physician, I’ve seen firsthand how broad, non-specific therapies often failed to stop the runaway inflammation that makes sepsis so deadly. It gives me great hope to finally see a fundamental shift is happening in sepsis research, one that places our mission at the forefront of modern medicine.\u0026nbsp;A wave of new scientific research confirms the future of sepsis care lies in a new direction.\u0026nbsp;The ...","published_at":"2025-07-03T13:57:36Z","author_name":"Dr. Isaac Eliaz (MD)","url":"/feed/183434","canonical_url":"https://wefunder.com/feed/183434"},{"id":183100,"entity_id":"wefunder:feed_item:183100","type":"FeedItem::Update","visibility":"public","title":"Is Public Awareness Enough?","preview":"Dear friends,\u0026nbsp;Not so long ago, the word “sepsis” was a mystery to the public. In fact, according to the Sepsis Alliance, only 19% of Americans had even heard of the term in 2003.\u0026nbsp;Today, thanks to tireless education and advocacy, that number has increased to 69%.\u0026nbsp;This dramatic shift is a victory worth celebrating, but it forces a critical question: Is awareness enough?The answer, simply, is no.This rise in awareness is a powerful reminder that:Education saves lives.Awareness dri...","published_at":"2025-06-19T19:32:17Z","author_name":"Dr. Isaac Eliaz (MD)","url":"/feed/183100","canonical_url":"https://wefunder.com/feed/183100"},{"id":182519,"entity_id":"wefunder:feed_item:182519","type":"FeedItem::Update","visibility":"public","title":"A Message of Hope from Dr. Eliaz","preview":"Dear Friends and Supporters,Throughout my decades in medicine and healing, I’ve consistently observed that true, lasting health comes from restoring the body's innate balance by addressing root causes, not just symptoms. This principle has been the bedrock of my research into Galectin-3 and its profound impact on our survival response and overall wellbeing.It’s deeply affirming to see the global sepsis research community now emphasizing what I’ve long believed in: the need for targeted therap...","published_at":"2025-05-23T15:12:16Z","author_name":"Dr. Isaac Eliaz (MD)","url":"/feed/182519","canonical_url":"https://wefunder.com/feed/182519"},{"id":182274,"entity_id":"wefunder:feed_item:182274","type":"FeedItem::Update","visibility":"public","title":"💡Dr. Eliaz Answers: How Do We Measure Galectin-3?","preview":"In our first \"Your Questions Answered\" segment, I address a crucial question from the community: How is Galectin-3 measured?Watch the video below where I explain the simple, clinically available blood test we use.\u0026nbsp;Understanding Gal-3’s link to inflammation, fibrosis, and conditions like sepsis, heart failure, and kidney disease is precisely why we believe targeting Gal-3 with XGal-3® holds truly transformative potential.Yours in health,\u0026nbsp;Isaac Eliaz, MD, MS, LAc🙌🏼 Great News—We’ve ex...","published_at":"2025-05-10T17:40:54Z","author_name":"Dr. Isaac Eliaz (MD)","url":"/feed/182274","canonical_url":"https://wefunder.com/feed/182274"},{"id":181994,"entity_id":"wefunder:feed_item:181994","type":"FeedItem::Update","visibility":"public","title":"Your Words, Our Inspiration","preview":"When we launched our Wefunder campaign, we hoped to connect with people who understood the urgent need for better solutions.I have been truly overwhelmed and deeply moved by the response since then.Hundreds of emails and comments have poured in, painting a vivid, often heart-wrenching, picture of sepsis's impact on so many lives.We've heard from dedicated ER doctors and nurses sharing their frontline experiences: \"As an RN, I'm excited about this technology.\"We've heard from courageous surviv...","published_at":"2025-04-29T19:02:56Z","author_name":"Dr. Isaac Eliaz (MD)","url":"/feed/181994","canonical_url":"https://wefunder.com/feed/181994"},{"id":181823,"entity_id":"wefunder:feed_item:181823","type":"FeedItem::Update","visibility":"public","title":"Eliaz Therapeutics on the Global Stage","preview":"To our valued Wefunder community,I was deeply honored to receive the news that our research has been selected for an opening day presentation at the International Society for Apheresis (ISFA) World Congress in Bangkok this July.Presenting our work, specifically \"Galectin-3 apheresis - a promising therapy for Sepsis and Sepsis Associated Acute Kidney Injury (SA-AKI),\" at the world's premier forum dedicated to this field is a significant milestone.For me, this invitation goes beyond academic re...","published_at":"2025-04-25T17:31:48Z","author_name":"Dr. Isaac Eliaz (MD)","url":"/feed/181823","canonical_url":"https://wefunder.com/feed/181823"},{"id":180654,"entity_id":"wefunder:feed_item:180654","type":"FeedItem::Update","visibility":"public","title":"FDA Grants XGal-3® Breakthrough Device Designation!","preview":"To our valued Wefunder community,Today marks a transformative milestone for Eliaz Therapeutics! I’m honored to share that the FDA has officially granted XGal-3® its coveted Breakthrough Device Designation.\u0026nbsp;\u0026nbsp;What is Breakthrough Device Designation?This prestigious recognition is reserved for innovative technologies addressing life-threatening conditions with no effective treatments. It signifies the FDA’s recognition of XGal-3®’s potential to fundamentally shift the course of sepsis ...","published_at":"2025-03-21T17:33:25Z","author_name":"Dr. Isaac Eliaz (MD)","url":"/feed/180654","canonical_url":"https://wefunder.com/feed/180654"},{"id":179525,"entity_id":"wefunder:feed_item:179525","type":"FeedItem::Update","visibility":"public","title":"[Update from Dr. Eliaz] A Simple Solution to a Complex Problem","preview":"To Our Valued Wefunder Followers and Investors,\u0026nbsp;Over the last several weeks, many of you have expressed an interest in learning more about the science behind our XGAL-3® technology. For those of you who are interested, I'd like to take a moment to offer a high-level examination of the elegance of our solution.With XGAL-3®, we've developed a specialized filter that works with standard hospital equipment to selectively remove excess Galectin-3 from the bloodstream. You can picture this fil...","published_at":"2025-02-17T15:18:28Z","author_name":"Alex Portera","url":"/feed/179525","canonical_url":"https://wefunder.com/feed/179525"},{"id":179424,"entity_id":"wefunder:feed_item:179424","type":"FeedItem::Update","visibility":"public","title":"[Update from Dr. Eliaz] Your Stories: Why Our Mission to Fight Sepsis Touches So Many Lives","preview":"To our valued Wefunder followers \u0026 investors,\u0026nbsp;Today I find myself deeply moved by the outpouring of stories and support my team has received from you—our growing community of investors—over the last several weeks. Every day, I receive messages from our Wefunder investors that remind me why our work at Eliaz Therapeutics is so vital.\u0026nbsp;What touches me most deeply are the stories of transformation. Our community includes both those who have experienced the healing power of addressing Ga...","published_at":"2025-02-13T18:27:19Z","author_name":"Alex Portera","url":"/feed/179424","canonical_url":"https://wefunder.com/feed/179424"},{"id":179423,"entity_id":"wefunder:feed_item:179423","type":"FeedItem::Update","visibility":"public","title":"Honoring Sepsis Survivors","preview":"During Sepsis Survivor Week (February 9-15), we pause to acknowledge both the devastating impact of sepsis and the resilience of its survivors. In the U.S., every hour, approximately 100 new patients face this deadly condition in ICUs.\u0026nbsp;But for those who survive, the journey doesn't end at discharge.Up to 50% of sepsis survivors experience long-term physical, emotional, and psychological challenges known as Post-Sepsis Syndrome. With each hour of delayed treatment increasing mortality ris...","published_at":"2025-02-10T19:33:10Z","author_name":"Alex Portera","url":"/feed/179423","canonical_url":"https://wefunder.com/feed/179423"},{"id":179339,"entity_id":"wefunder:feed_item:179339","type":"FeedItem::Update","visibility":"public","title":"What is the Survival Paradox?","preview":"“The Survival Paradox is an excellent guide for anyone struggling with chronic illness. Read it carefully and start your journey to wholeness and wellbeing.”—Deepak Chopra, MDTo Our Valued Wefunder Community,\u0026nbsp;As many of you know, my book “The Survival Paradox” explores how our body's protective responses—though essential for survival—can become destructive forces when they persist unchecked. Today, this idea has received powerful validation from a groundbreaking study published in Cell, ...","published_at":"2025-02-06T15:57:52Z","author_name":"Alex Portera","url":"/feed/179339","canonical_url":"https://wefunder.com/feed/179339"},{"id":179261,"entity_id":"wefunder:feed_item:179261","type":"FeedItem::Update","visibility":"public","title":"Former FDA Director Joins Our Regulatory Path","preview":"We are thrilled to announce that Dr. Susan Alpert, former Director of the FDA’s Office of Device Evaluation, is joining Eliaz Therapeutics as a regulatory strategist!Dr. Alpert directed all U.S. medical device evaluations at the FDA from 1993 to 1999, during her remarkable 13-year tenure there. She then took her talents to Medtronic, one of the world's largest medical technology companies, where she served as Senior Vice President and Chief Regulatory Officer from 2005 to 2011.\u0026nbsp;Why This ...","published_at":"2025-02-04T14:06:36Z","author_name":"Alex Portera","url":"/feed/179261","canonical_url":"https://wefunder.com/feed/179261"}],"q_and_a":[{"id":297608,"entity_id":"wefunder:comment:297608","question":"how is this different / compared to current available solution like Oxiris , we know is holt the process , it might improve the patient temporarily but wont change the outcome of sepsis ...","author_name":"Ali Buzaid","votes":5,"created_at":"2024-12-07T09:29:16Z","canonical_url":"https://wefunder.com/eliaz.therapeutics#question-297608","answers":[{"id":297626,"entity_id":"wefunder:comment:297626","answer":"XGAL-3 is fundamentally different than Oxiris. OXiris is a blood filtration system used in conjunction with hemodialysis. It is used at a much later stage in the sepsis process, when the patient already has kidney damage/failure that required dialysis in the ICU. It requires high blood flow of 150-200ml/minute. The 90 days outcome of a meta analysis study from 2023 showed that 90-day mortality, ICU and hospital mortality, and length of hospital stay did not improve. XGAL-3 is a highly selective therapeutic apheresis filter. It can be used on all patients and at much lower blood flow rates. It can and will be used , starting on day of admission to the ICU and can be repeated as needed. Our small animal and large animal (LPS induced porcine sepsis model) sepsis trials that will be published soon show a significant improvement of the sepsis process with positive effects on the damaging mechanism of action in sepsis, multi-organ damage, and mortality. Our IP will also allow us to combine the XGAL-3 with other therapies that are indicated. I hope that this is helpful. Thank you for your interest in our work, Isaac","author_name":"Dr. Isaac Eliaz (MD)","votes":3,"created_at":"2024-12-07T18:20:26Z"}]},{"id":310641,"entity_id":"wefunder:comment:310641","question":"Why cant we see how many have invested? Inspires a lot of people to invest more.","author_name":"Thomas Klauset Aurdal","votes":3,"created_at":"2025-07-01T09:39:25Z","canonical_url":"https://wefunder.com/eliaz.therapeutics#question-310641","answers":[{"id":310730,"entity_id":"wefunder:comment:310730","answer":"Greetings, thanks for the question. You actually can see how many invested. If you go to our main landing page and hover over the 'i' icon next to the total amount raised, you can see how many total investors there are. Thanks, Bryan","author_name":"Bryan Knipe","votes":0,"created_at":"2025-07-02T05:05:49Z"}]},{"id":307363,"entity_id":"wefunder:comment:307363","question":"Maybe theres some overlap between bacteria in abscesses and sepsis. Maybe you also can make an product for abscesses out of this. Inject something into abscesses befor you have to do it more invasively and cut it open which is very often the end result. Sometimes sepsis is the result of abscesses. Abscesses are very prevalenent in transplant patients in which immune system are suppressed with medication. Also in illegal drug ijnectors, substance abusers. Or maybe a sort of cream can be made. As I see it this XGal has potentially far wider potential.","author_name":"Thomas Klauset Aurdal","votes":2,"created_at":"2025-05-02T10:00:34Z","canonical_url":"https://wefunder.com/eliaz.therapeutics#question-307363","answers":[{"id":307417,"entity_id":"wefunder:comment:307417","answer":"Hello Thomas, Thanks for your comment. We agree that Galectin-3 plays a role in a wide range of biological processes and disease areas beyond our current focus. While our primary goal is to treat critically ill patients with sepsis and acute kidney injury in the ICU, we’re very aware of the broader potential this platform could have in other indications over time. We’re excited by the possibilities and always appreciate thoughtful engagement like yours. If you believe in the vision and want to help accelerate the work, we’d love to have your support as an investor. If you have more in-depth or speculative questions about additional applications, it may probably be best to continue the conversation off-platform. Please reach out directly to me at bryan@eliaztherapeutics.com. Best regards, Bryan Knipe Eliaz Therapeutics","author_name":"Bryan Knipe","votes":0,"created_at":"2025-05-03T17:46:54Z"}]},{"id":306585,"entity_id":"wefunder:comment:306585","question":"Why are you closing in 5d if goal is 5M?","author_name":"Thomas Klauset Aurdal","votes":2,"created_at":"2025-04-22T17:15:39Z","canonical_url":"https://wefunder.com/eliaz.therapeutics#question-306585","answers":[{"id":306599,"entity_id":"wefunder:comment:306599","answer":"Hi Thomas, Great question.! We are not closing our Wefunder campaign. It is a technicality that is based on the initial campaign closing date and the fact that we oversubscribed. We already have another 12 months extension, so we aer not closing the campaign! And once our audited financials are done (10-14 days), we will formally take in the oversubscribed funds and actively pursue our new goal - $5M.","author_name":"Dr. Isaac Eliaz (MD)","votes":0,"created_at":"2025-04-22T19:20:54Z"}]},{"id":305971,"entity_id":"wefunder:comment:305971","question":"Maybe then it can be used in senescence as anti-aging therapy? https://pubmed.ncbi.nlm.nih.gov/37208177/","author_name":"Thomas Klauset Aurdal","votes":2,"created_at":"2025-04-14T15:05:17Z","canonical_url":"https://wefunder.com/eliaz.therapeutics#question-305971","answers":[{"id":306116,"entity_id":"wefunder:comment:306116","answer":"The answer is yes, This is why it's a platform technology. But the initial focus in on sepsis.","author_name":"Dr. Isaac Eliaz (MD)","votes":0,"created_at":"2025-04-16T04:15:54Z"}]},{"id":305915,"entity_id":"wefunder:comment:305915","question":"Does it exists various types of sepsis? If so does this addresses more then one or all? Some organ transplant survivors gets sepsis few days or week after transplantation? Will this help that patient group?","author_name":"Thomas Klauset Aurdal","votes":2,"created_at":"2025-04-12T15:36:07Z","canonical_url":"https://wefunder.com/eliaz.therapeutics#question-305915","answers":[{"id":305966,"entity_id":"wefunder:comment:305966","answer":"Thank you Thomas for your excellent question. XGAL-3 addresses the immune and inflammatory dysregulation underlying the sepsis process. This process is almost universal in sepsis. I plan to discuss the scientific basis of XGAL-3 in greater detail in an upcoming webinar. Thank you for your interest in XGAL-3, Isaac","author_name":"Dr. Isaac Eliaz (MD)","votes":0,"created_at":"2025-04-14T06:02:54Z"}]},{"id":304507,"entity_id":"wefunder:comment:304507","question":"Hi, do you have a link to an fda webpage or can post the letter from the fda so that the breakthrough designation can be verified","author_name":"Noah Posner","votes":2,"created_at":"2025-03-22T18:56:41Z","canonical_url":"https://wefunder.com/eliaz.therapeutics#question-304507","answers":[{"id":304553,"entity_id":"wefunder:comment:304553","answer":"Hi Noah, Thank you for your question. The FDA formal approval notice includes confidential information. We are reviewing the letter to see what needs to be removed due to confidentiality, and will post the letter without the confidential information soon. I hope that this helps. all the best, Isaac","author_name":"Dr. Isaac Eliaz (MD)","votes":1,"created_at":"2025-03-24T02:25:35Z"}]},{"id":303686,"entity_id":"wefunder:comment:303686","question":"I live in Ontario, Canada, have US citizenship by birth, and acquired citizenship in Canada in addition. I tried to open an account with Wefunder. I entered my name, residency and SSN. The next page said something is wrong. I then entered my SIN, the Canadian tax number. The next page again said something is wrong. I am not a US resident. The only thing I can think of that might be wrong is that residents of Ontario and Quebec are by law not allowed to participate in some investments before a company issues stock. Is that what prevented me from being able to use Wefunder? If so, is there any way to get around this blocking? I have siblings in the Carolinas. My children all live in Ontario and Quebec.","author_name":"Nancy Schmeing","votes":2,"created_at":"2025-03-07T19:35:58Z","canonical_url":"https://wefunder.com/eliaz.therapeutics#question-303686","answers":[{"id":303719,"entity_id":"wefunder:comment:303719","answer":"Hi Nancy, thank you for your interest in ETI. You are correct that residents of Ontario and Quebec are not allowed to invest in USA based crowd funding platforms. I will ask the Wefunder team to check if there is a solution. I will also ask Bryan Knype, our director of investor relationships to reach out to you. With gratitude, Isaac","author_name":"Dr. Isaac Eliaz (MD)","votes":0,"created_at":"2025-03-08T06:30:09Z"},{"id":303928,"entity_id":"wefunder:comment:303928","answer":"Hello Nancy - What Dr. Eliaz mentions is correct. The Canadian provinces of Alberta, British Columbia, Ontario, and Quebec are currently barred from investing on the Wefunder platform at the requests of the governments there. If you send me an email, I can see what I can do to help: Bryan@eliaztherapeutics.com Thanks, Bryan","author_name":"Bryan Knipe","votes":0,"created_at":"2025-03-12T03:53:56Z"}]},{"id":302503,"entity_id":"wefunder:comment:302503","question":"I work in a headcase medical named the Bermuda Hospitals Board in the country of Bermuda","author_name":"George Simons","votes":2,"created_at":"2025-02-18T18:20:03Z","canonical_url":"https://wefunder.com/eliaz.therapeutics#question-302503","answers":[{"id":304551,"entity_id":"wefunder:comment:304551","answer":"Thank you George. With your permission, we will reach out to you with support when needed.","author_name":"Dr. Isaac Eliaz (MD)","votes":0,"created_at":"2025-03-24T02:20:58Z"}]},{"id":321942,"entity_id":"wefunder:comment:321942","question":"Back in April it was said that you had a 1 year extension. I would like to invest, however, there is no option on you page to do so. Is there another way? Or did the extension not get approved? If so, why? Thank you.","author_name":"Rebecca Keltie","votes":1,"created_at":"2025-12-29T06:45:07Z","canonical_url":"https://wefunder.com/eliaz.therapeutics#question-321942","answers":[{"id":322021,"entity_id":"wefunder:comment:322021","answer":"Hello Rebecca - Yes, you can still invest. Please send me an email: Bryan@eliaztherapeutics.com . Happy to send you the information on how to do that. Thanks, Bryan","author_name":"Bryan Knipe","votes":0,"created_at":"2025-12-30T16:23:42Z"}]},{"id":315905,"entity_id":"wefunder:comment:315905","question":"Hope you can add at your website possibility to sign up for newsletter.","author_name":"Thomas Klauset Aurdal","votes":1,"created_at":"2025-09-29T12:15:48Z","canonical_url":"https://wefunder.com/eliaz.therapeutics#question-315905","answers":[]},{"id":315572,"entity_id":"wefunder:comment:315572","question":"when do you expect this product to be approved and be put into medical use? When should I expect to receive a 1099 or k-1 each year for tax reporting purposes. I would hate to have to file an extension on my tax return waiting for these tax documents each year. Thanks","author_name":"Cathy Prvanov","votes":1,"created_at":"2025-09-23T21:59:18Z","canonical_url":"https://wefunder.com/eliaz.therapeutics#question-315572","answers":[{"id":315575,"entity_id":"wefunder:comment:315575","answer":"Hi Cathy, Thank you for your question. It will be 3 years before any revenues will be generated. I am not an expert in taxation, but I don't think that this will be a K-1. Than you for your interest in ETI. All the best, Isaac","author_name":"Dr. Isaac Eliaz (MD)","votes":1,"created_at":"2025-09-23T22:26:06Z"}]},{"id":315372,"entity_id":"wefunder:comment:315372","question":"One of my close relatives passed away last year in india due to sephis. That was the first time I heard about Sephis. The doctors said it is very strong kind of infections. They started giving heavy doses of anti boitic which initially helped but later Sephis resited all these anti biotics. Is there no cure for sephis at present.","author_name":"Harish Damodhardas Asar","votes":1,"created_at":"2025-09-20T14:11:24Z","canonical_url":"https://wefunder.com/eliaz.therapeutics#question-315372","answers":[{"id":315378,"entity_id":"wefunder:comment:315378","answer":"Dear Harish, I am sorry to hear about your close relative. Currently there is no approved treatment for sepsis. Only supportive care and antimicrobial treatment for the infection source. Sepsis is no longer defined as an infection. It's the body's immune and inflammatory dysregulated response to infection. XGAL-3 aims to address this devastating process and stop it. This is what we observed happening in our porcine LPS induced sepsis studies.","author_name":"Dr. Isaac Eliaz (MD)","votes":0,"created_at":"2025-09-20T16:41:58Z"}]},{"id":314833,"entity_id":"wefunder:comment:314833","question":"Do you know about LSN: https://www.lifesciencenation.com/workshops/","author_name":"Thomas Klauset Aurdal","votes":1,"created_at":"2025-09-12T18:25:31Z","canonical_url":"https://wefunder.com/eliaz.therapeutics#question-314833","answers":[]},{"id":314360,"entity_id":"wefunder:comment:314360","question":"Hello DR. IE Thanks for the prompt replies. Any idea when a revenue stream will start ? the burn rate is high, any details ? How much runway do you have left with current funding ?","author_name":"Silvr Tabz","votes":1,"created_at":"2025-09-04T19:23:23Z","canonical_url":"https://wefunder.com/eliaz.therapeutics#question-314360","answers":[{"id":314418,"entity_id":"wefunder:comment:314418","answer":"Dear Silvr, please reach out to Bryan Knipe, our director of investors relationships at bryan@eliaztherapeutics.com . All the best, Isaac","author_name":"Dr. Isaac Eliaz (MD)","votes":0,"created_at":"2025-09-05T07:05:56Z"}]},{"id":314104,"entity_id":"wefunder:comment:314104","question":"1) Any update of FDA approval ? 2) Any update on Terumo since a 2022 collaboration ?","author_name":"Silvr Tabz","votes":1,"created_at":"2025-09-02T03:10:09Z","canonical_url":"https://wefunder.com/eliaz.therapeutics#question-314104","answers":[{"id":314106,"entity_id":"wefunder:comment:314106","answer":"Dear Silvr, Thank you for your questions. With the FDA breakthrough designation in place, we aer progressing on the regulatory path in multiple areas. These includes column manufacturing, and antibody manufacturing. We are also progressing with our clinical road map and clinical trial design. We already started our pre therapeutic diagnostic trials and the first fwe patients have been enrolled and completed. We continue to have a strong collaboration with Terumo BCT. Some of the details are confidential in nature. Warmest wisehs, Isaac","author_name":"Dr. Isaac Eliaz (MD)","votes":0,"created_at":"2025-09-02T04:31:19Z"}]},{"id":313874,"entity_id":"wefunder:comment:313874","question":"Does science know if Progerin is one of causes for sepsis? Maybe you can remove that protein too if shown to be detrimental. https://www.fightaging.org/archives/2025/08/progerin-expression-may-play-a-role-in-chronic-kidney-disease/","author_name":"Thomas Klauset Aurdal","votes":1,"created_at":"2025-08-28T11:56:12Z","canonical_url":"https://wefunder.com/eliaz.therapeutics#question-313874","answers":[]},{"id":312727,"entity_id":"wefunder:comment:312727","question":"Do you plan on using this prophylactically, especially for patients with the multi-susceptible and/or coeliac genes (95% of CIRS patients)? Or what about for non-oncological haematology ward patients who just receive gut damaging ABx IV for days until Filgrastin kicks the immune system back into gear? Why wait until ICU?","author_name":"Sha Si","votes":1,"created_at":"2025-08-08T08:28:20Z","canonical_url":"https://wefunder.com/eliaz.therapeutics#question-312727","answers":[{"id":312849,"entity_id":"wefunder:comment:312849","answer":"hi Sha Si, Thank you for your question. The XGAL-3 is a therapeutic device, aimed at changing the outcome of devastating conditions with no current good treatment. Preventative is very important, but done on a different scale using other methods. All the best, Isaac","author_name":"Dr. Isaac Eliaz (MD)","votes":1,"created_at":"2025-08-09T04:27:48Z"}]},{"id":311093,"entity_id":"wefunder:comment:311093","question":"Have you seen this. It seems like your product can be used in far more also aging and are heavily undervalued: Study of central nervous system available inhibitors targeting microglial galectin-3 in neurodegenerative diseases - https://halric.eu/pilot-project/central-nervous-system-available-inhibitors-targeting-microglial-galectin-3-in-neurodegenerative-diseases/","author_name":"Thomas Klauset Aurdal","votes":1,"created_at":"2025-07-10T09:38:14Z","canonical_url":"https://wefunder.com/eliaz.therapeutics#question-311093","answers":[]},{"id":310694,"entity_id":"wefunder:comment:310694","question":"what is the situation if I want to sell my investment? Any time??","author_name":"Shakti Carola Navran","votes":1,"created_at":"2025-07-01T20:23:25Z","canonical_url":"https://wefunder.com/eliaz.therapeutics#question-310694","answers":[{"id":310729,"entity_id":"wefunder:comment:310729","answer":"Thanks for the question! This investment is structured as a SAFE (Simple Agreement for Future Equity). It can’t be sold or transferred, as it’s not a tradable security. Instead, your SAFE will convert into shares during our first priced equity round (such as a Series A). From that point forward, your investment becomes liquid only upon an exit event, like an acquisition or IPO. Hope that helps clarify. Feel free to reach out to me directly if you’d like to discuss further: Bryan@eliaztherapeutics.com","author_name":"Bryan Knipe","votes":1,"created_at":"2025-07-02T05:01:04Z"}]},{"id":310449,"entity_id":"wefunder:comment:310449","question":"How close are you to getting approval for your device in Europe?","author_name":"Juliana Hahn","votes":1,"created_at":"2025-06-27T16:55:17Z","canonical_url":"https://wefunder.com/eliaz.therapeutics#question-310449","answers":[{"id":310460,"entity_id":"wefunder:comment:310460","answer":"Hi Juliana, We are probably looking at 2028-2029 for Europe/CE mark. Thank you for your interest in ETI. All the best, Isaac","author_name":"Dr. Isaac Eliaz (MD)","votes":0,"created_at":"2025-06-27T19:25:18Z"}]},{"id":309381,"entity_id":"wefunder:comment:309381","question":"Can you something with this: https://www.benzinga.com/partner/biotech/25/06/45790529/kamada-wants-to-do-more-for-organ-transplant-patients-increases-efforts-to-build-awareness-of-its https://www.kamada.com/","author_name":"Thomas Klauset Aurdal","votes":1,"created_at":"2025-06-08T17:53:59Z","canonical_url":"https://wefunder.com/eliaz.therapeutics#question-309381","answers":[]},{"id":309064,"entity_id":"wefunder:comment:309064","question":"Have you seen this company. At this presentation they write about something calle a-Gal A. Is it some overlap with what youre doing? Maybe you can work with them and expand your market: https://www.sangamo.com/wp-content/uploads/2025/02/Hughes020625_46_Isaralgagene-civaparvovec_6Feb2025_Final-Feb-13.pdf","author_name":"Thomas Klauset Aurdal","votes":1,"created_at":"2025-06-03T20:31:57Z","canonical_url":"https://wefunder.com/eliaz.therapeutics#question-309064","answers":[]},{"id":309017,"entity_id":"wefunder:comment:309017","question":"i tHOUGHT i HAD INVESTED BUT NO RECORD WAS SENT ME. pLEASE ADVISE.","author_name":"Ward A Weaver","votes":1,"created_at":"2025-06-03T18:40:26Z","canonical_url":"https://wefunder.com/eliaz.therapeutics#question-309017","answers":[{"id":309022,"entity_id":"wefunder:comment:309022","answer":"Hello Ward - Can you email me directly and I will take a look at it for you? Thanks, Bryan - Bryan@eliaztherapeutics.com","author_name":"Bryan Knipe","votes":1,"created_at":"2025-06-03T19:16:27Z"}]},{"id":308337,"entity_id":"wefunder:comment:308337","question":"Maybe you should try to be part of Longevity Investor Network (LIN), so you can access more funds: https://www.lifespan.io/news/longevity-investor-network-2024-end-of-year-update/","author_name":"Thomas Klauset Aurdal","votes":1,"created_at":"2025-05-19T11:57:39Z","canonical_url":"https://wefunder.com/eliaz.therapeutics#question-308337","answers":[]}],"faq":[{"question":"What do I get if I invest? Is it a stock or share?","answer":"Hi Robert, When you invest in Eliaz Therapeutics via our Wefunder campaign, you receive a Simple Agreement for Future Equity (SAFE). This isn’t a traditional stock or share immediately, but rather a contractual agreement that converts into equity (ownership in the company) during a future fundraising round, such as our upcoming Series A. The benefit of investing in our SAFE now is that if it converts into equity into the future, this will be at the SAFE's valuation cap rather than the valuati..."},{"question":"I completed the investment form as an email option and was given a strong password to continue but after I completed everything the system said it could not accept my investment from my location. Is this investment opportunity only available in the USA? I am a Canadian resident.","answer":"Hi Candace, thank you for your interest in ETI. Certain provinces in Canada can't participate in crowdfunding, at least through WEFunder. There may be alternate ways to do it. What amount were you looking at investing? with gratitude, Isaac"},{"question":"The entity making the investment is a Family Trust. It does not have an EIN. Should I use a social security number","answer":"Hi, I think that SS# is fine , but to make sure I am checking with WeFunder and will get back to you ASAP. Thank you for your support and trust in us. all the best, Isaac"},{"question":"I appreciate that you're submitting your Breakthough Designation Application for the FDA that will fast track some of the process, but what's the regulatory path forward and an anticipated timeline for getting this to patients?","answer":"Thank you, Jason, for your question. We are currently engaged in non GLP and GLP large animal safety studies, while finalizing the column prototype. The anticipated timeline is to file for XGAL-3 clinical trials approval mid 2025 and start the XGAL-3 therapeutic trials early 2026, possibly late 2025. We are already in discussions with a number of excellent medical centers in the USA and outside the USA that are interested in participating. We are also planning to conduct pre-therapeutic diagn..."},{"question":"how is this different / compared to current available solution like Oxiris , we know is holt the process , it might improve the patient temporarily but wont change the outcome of sepsis ...","answer":"XGAL-3 is fundamentally different than Oxiris. OXiris is a blood filtration system used in conjunction with hemodialysis. It is used at a much later stage in the sepsis process, when the patient already has kidney damage/failure that required dialysis in the ICU. It requires high blood flow of 150-200ml/minute. The 90 days outcome of a meta analysis study from 2023 showed that 90-day mortality, ICU and hospital mortality, and length of hospital stay did not improve. XGAL-3 is a highly selecti..."}]}}}